Weimin Li
Harbin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Short-term survival of dual SGLT2i-MRA and four-class guideline-directed medical therapy in acute heart failure.
Journal: European journal of heart failure
Published: February 21, 2026
Phenotyping HFpEF by Using Left Ventricular End-Diastolic Dimension and ITS Relationship With Postdischarge 1-Year Mortality.
Journal: JACC. Heart failure
Published: September 22, 2025
Nationwide implementation of heart failure therapies: National Heart Failure Center Accreditation Program (HF-CAP) in China.
Journal: European journal of heart failure
Published: April 04, 2025
Mortality in patients admitted to hospital with heart failure in China: a nationwide Cardiovascular Association Database-Heart Failure Centre Registry cohort study.
Journal: The Lancet. Global health
Published: September 17, 2023
Sex-specific characteristics and outcomes in hospitalized heart failure with preserved ejection fraction: the China Cardiovascular Association Database-Heart Failure Center Registry.
Journal: European heart journal
Published: January 28, 2023
Clinical characteristics and 1-year outcomes in hospitalized patients with heart failure with preserved ejection fraction: results from the China Cardiovascular Association Database-Heart Failure Center Registry.
Journal: European journal of heart failure
Published: June 29, 2022
β3 adrenergic receptor antagonist SR59230A exerts beneficial effects on right ventricular performance in monocrotaline-induced pulmonary arterial hypertension.
Journal: Experimental and therapeutic medicine
Published: December 14, 2018
Valsartan inhibits RhoA-ROCK2-MYL pathway in rat model of alcoholic cardiomyopathy.
Journal: Experimental and therapeutic medicine
Published: March 14, 2018
Critical role of the chymase/angiotensin-(1-12) axis in modulating cardiomyocyte contractility.
Journal: International journal of cardiology
Published: January 19, 2018
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure.
Journal: Journal of the American College of Cardiology
Published: January 17, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026